These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 26859106)

  • 21. Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.
    Tsai JN; Zhu Y; Foley K; Lee H; Burnett-Bowie SA; Neer RM; Leder BZ
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2718-23. PubMed ID: 25933031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parathyroid hormone as an anabolic skeletal therapy.
    Rubin MR; Bilezikian JP
    Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.
    Ma YL; Zeng Q; Donley DW; Ste-Marie LG; Gallagher JC; Dalsky GP; Marcus R; Eriksen EF
    J Bone Miner Res; 2006 Jun; 21(6):855-64. PubMed ID: 16753016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
    O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
    Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Teriparatide--new value in osteoporosis treatment: treatment guidelines].
    Korsić M; Kastelan D
    Reumatizam; 2006; 53(2):77-81. PubMed ID: 17580560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.
    Ramchand SK; Chiang CY; Zebaze RM; Seeman E
    Osteoporos Int; 2016 Feb; 27(2):821-5. PubMed ID: 26458389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program.
    Papaioannou A; Khan A; Belanger A; Bensen W; Kendler D; Theoret F; Amin M; Brekke L; Erdmann M; Walker V; Adachi JD
    Curr Med Res Opin; 2015; 31(7):1391-401. PubMed ID: 25993017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
    Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
    J Med Econ; 2010; 13(3):381-92. PubMed ID: 20604678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone biology, signaling pathways, and therapeutic targets for osteoporosis.
    Iñiguez-Ariza NM; Clarke BL
    Maturitas; 2015 Oct; 82(2):245-55. PubMed ID: 26255682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.
    Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Sakellariou G; Savvidis M; Papatheodorou A; Kokkoris P; Terpos E
    Expert Opin Ther Targets; 2015 Mar; 19(3):299-306. PubMed ID: 25395071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
    Lems WF; Hamdy NA; Netelenbos JC
    Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination anabolic and antiresorptive therapy for osteoporosis.
    Cusano NE; Bilezikian JP
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.
    Anastasilakis AD; Polyzos SA; Makras P; Trovas G; Yavropoulou MP; Tournis S
    J Clin Densitom; 2021; 24(4):591-596. PubMed ID: 33541775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
    J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on "Variability of denosumab densitometric response in postmenopausal osteoporosis".
    Torrente-Segarra V; Roig-Vilaseca D
    Rheumatol Int; 2018 Jun; 38(6):1161-1162. PubMed ID: 29546636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis.
    Yavropoulou MP; Anastasilakis AD; Makras P; Papatheodorou A; Rauner M; Hofbauer LC; Tsourdi E
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32521543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.